Bausch + Lomb Corporation (BLCO) is a publicly traded Healthcare sector company. As of May 20, 2026, BLCO trades at $16.00 with a market cap of $5.74B and a P/E ratio of -26.08. BLCO moved -0.03% today. Year to date, BLCO is -3.57%; over the trailing twelve months it is +37.87%. Its 52-week range spans $10.45 to $21.69. Analyst consensus is neutral with an average price target of $18.60. Rallies surfaces BLCO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bausch + Lomb jumps after Q1 sales growth and raised 2026 guidance: Bausch + Lomb shares are higher after the company reported Q1 2026 revenue of $1.244 billion and raised full-year 2026 revenue and adjusted EBITDA guidance. Management cited strong performance across Vision Care, Surgical, and Pharmaceuticals, with Pharmaceuticals boosted by MIEBO (+33%) and XIIDRA (+30%).
| Metric | Value |
|---|---|
| Price | $16.00 |
| Market Cap | $5.74B |
| P/E Ratio | -26.08 |
| EPS | $-0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.69 |
| 52-Week Low | $10.45 |
| Volume | 310.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.21B |
| Net Income | $-211.00M |
| Gross Margin | 0.00% |
12 analysts cover BLCO: 0 strong buy, 4 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $18.60.